Sorrento is a hot stock. $SRNE. What has it accomplished?Lots. Set up a T2BF Account complete with $100,000. Pass all phases.Then trade SRNE stock because:1. PSS lawsuit worth $1.2 Billion+ potential 2. BARDA funding, other government funding 3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake) 4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial 5. STI-1499 (COVIGUARD)FDA IND approval 6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application 7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now). 8. I-Cell COVID 19 Vaccine IND approval 9. Sorrento and SmartPharm gene encoded vaccine IND application 10. Sorrento and MabPharma ACE MAB IND approval 11. Phase 1 trial data of CD 38 for Amyloidosis 12. SP-102 phase 3 results 13. CD38 lymphoma IND 14. RTX arthritis news 15. RTX knee pain news 16. RTX cancer pain news 17. RTX ARDS treatment 18. Scilex potential IPO 19. FDA approval of COVI-TRACK 20. Sales begin for COVI-TRACK 21. Several cancer trials with first-in-class DAR-T are coming 22. Abivirtinib phase 2 in Covid begins in August 23. Water soluble CBD partnership 24. Covid T-VIVA-19 Vaccine enters clinic 25. COVI-TRACE saliva test enters clinic 26. COVI-TRACE gains approval 27. SOFUSA delivery phase 1b cancer trial 28. Analysts target prices are increasing steadily. $30 is latest 29. Institutions are buying. Up from 18% to 26% this week alone 30. Insiders holding solid at 34% $SRNE, Sorrento Therapeutics, Inc. / H1